INEP medical s.r.o.
- Address
- lock Available on a paid plan
Psychiatry and Depression Research
At INEP medical s.r.o. in Prague, a major focus is on major depressive disorder and treatment-resistant depression, with studies also addressing anhedonia and relapse prevention. These trials are designed to test new treatment options, improve symptom control, and better understand long-term benefit in people who have not responded well to standard antidepressants.
- Major depressive disorder and treatment-resistant depression
- Anhedonia and anxious distress in depression
- Testing new adjunctive and standalone therapies for depressive symptoms
- Evaluating relapse prevention and long-term safety
This research reflects a strong emphasis on finding more effective and durable approaches for complex depressive illness.
Alzheimer’s Disease and Neuropsychiatric Symptoms
The site is actively studying Alzheimer’s disease across several related problems, including psychosis, agitation, and cognitive impairment. The goal of these trials is to assess whether new therapies can reduce behavioral symptoms, support thinking and functioning, and improve care for people living with dementia-related complications.
- Alzheimer’s disease and mild to moderate Alzheimer’s disease
- Agitation and psychosis associated with Alzheimer’s disease
- Cognitive and global functioning in dementia
- Testing treatments aimed at symptom relief and better daily functioning
This area shows a clear interest in both behavioral and cognitive aspects of neurodegenerative disease.
Anxiety, Schizophrenia, and Cognitive Disorders
Another important research stream at INEP medical s.r.o. covers generalized anxiety disorder, schizophrenia, and cognitive disorder. These studies are evaluating potential new ways to ease anxiety symptoms, improve cognition, and address persistent challenges linked to psychotic disorders and related cognitive problems.
- Generalized anxiety disorder
- Schizophrenia and cognitive impairment associated with schizophrenia
- Cognitive disorder and related mental functioning issues
- Assessing symptom improvement and treatment tolerability
The work in this field aims to broaden options for patients with difficult-to-treat psychiatric and cognitive conditions.
Neurology, Migraine, Epilepsy, and Pain
The site also conducts trials in nervous system diseases and musculoskeletal diseases, including migraine, refractory partial onset epilepsy, tardive dyskinesia, and chronic low back pain. These studies are focused on improving prevention, reducing attack frequency or symptom burden, and evaluating whether new therapies can offer better relief for people with ongoing neurological or pain-related conditions.
- Migraine prevention and acute migraine treatment
- Drug-resistant focal onset seizures and epilepsy control
- Tardive dyskinesia symptom reduction
- Chronic non-specific low back pain and pain relief
This portfolio highlights a broader interest in both neurological symptom management and persistent pain conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in INEP medical s.r.o.
lock Showing 1 of 36 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Azetukalner in Patients with Moderate-to-Severe Major Depressive Disorder | Xenon Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aticaprant | 3 | Unknown | 2023-06-12 | 2024-12-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.